Skip to content

Frontlight ResearchEarly access

Institution

Memorial Sloan Kettering Cancer Center

New York, United StatesWebsite

Also known as: New York Cancer Hospital · MSK · MSKCC

1,209running trials
443closed trials
5researchers
122,019publications (OpenAlex)

Researchers

Running trials

Recruiting
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
NCT07437963· Phase 1/2· National Cancer Institute (NCI)· Source
Recruiting
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
NCT07605416· Phase 2· National Cancer Institute (NCI)· Source
Not yet recruiting
A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma
NCT07799220· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Not yet recruiting
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
NCT07313852· Phase 1/2· Memorial Sloan Kettering Cancer Center· Source
Not yet recruiting
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
NCT06941480· Phase 1· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of Ropeg-Interferon in People With Polycythemia Vera
NCT07886801· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
NCT07895498· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
NCT07890415· Phase 3· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
NCT07293247· Phase 2· Alliance for Clinical Trials in Oncology· Source
Recruiting
Researching the Effect of Exercise on Cancer
NCT04589468· City of Hope Medical Center· Source
Recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
NCT07741877· Phase 2· Iovance Biotherapeutics, Inc.· Source
Not yet recruiting
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
NCT07691489· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Enrolling by invitation
Study of Vaping Use Among Adolescent and Young Adult Patients With Cancer
NCT07860801· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991· Phase 1· Charm Therapeutics· Source
Recruiting
A Study of Treatment Delivery Preference In People With Kidney Cancer
NCT07872553· Phase 4· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979· Phase 3· Akeso· Source
Not yet recruiting
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
NCT07662928· Phase 2· AIDS Malignancy Consortium· Source
Recruiting
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
NCT07723703· Phase 1· Amphista Therapeutics Ltd· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
NCT07804186· Phase 3· IDEAYA Biosciences· Source
Recruiting
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
NCT07818018· Phase 1/2· Memorial Sloan Kettering Cancer Center· Source
Not yet recruiting
A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
NCT07540832· Phase 1/2· Zhejiang Haichang Biotech Co., Ltd.· Source
Recruiting
A Study of Armored CAR T Cells in People With Cancer
NCT07783477· Phase 1· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of Stereotactic Radiosurgery (SRS) in People With Brain Cancer Having Tumor Resection Surgery
NCT07802353· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
NCT07493304· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Study of Romosozumab in People With Breast Cancer and Osteoporosis
NCT07776613· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
NCT07768436· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Radiation Therapy Approaches for People With Prostate Cancer
NCT07751159· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Not yet recruiting
PRAISE-IR Versus CIBMTR Controls
NCT07717164· Miltenyi Biomedicine GmbH· Source
Recruiting
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680· Phase 2· Bristol-Myers Squibb· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· Phase 2· Verastem, Inc.· Source
Recruiting
A Study of Luspatercept in People With Anemia
NCT07725497· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
NCT05751434· Phase 2· City of Hope Medical Center· Source
Recruiting
Delayed Toxicities Post-CAR-T
NCT07665307· Icahn School of Medicine at Mount Sinai· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287· Phase 2· Pfizer· Source
Recruiting
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
NCT07698899· Phase 1· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of Lung Cancer Risk
NCT07701733· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of a New PET Scanner in People With Cancer
NCT07690917· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source
Recruiting
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
NCT07671339· Phase 1· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT07660055· Phase 1· Novartis Pharmaceuticals· Source
Recruiting
A Study of CRD3874-SI in People With Leukemia
NCT07661095· Phase 1· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study of a Urine Test to Detect Colorectal Cancer
NCT07649057· Memorial Sloan Kettering Cancer Center· Source
Recruiting
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
NCT07012044· Phase 1· National Cancer Institute (NCI)· Source
Recruiting
A Study of a Side Effects and Resource Navigation Program for People With Cancer
NCT07646847· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· Phase 3· Immuneering Corporation· Source
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820· Phase 2· Elevar Therapeutics· Source

Showing 50 of 1209.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers104 recruiting
Lung cancer101 recruiting
Colorectal cancer50 recruiting
Prostate cancer49 recruiting
Ovarian cancer46 recruiting
Multiple myeloma41 recruiting
Sarcoma40 recruiting
Pancreatic cancer39 recruiting
Acute myeloid leukaemia38 recruiting
Bladder cancer37 recruiting
Endometrial cancer34 recruiting
Metastatic breast cancer28 recruiting
Gastric and oesophageal cancer27 recruiting
Head and neck cancer27 recruiting
Acute lymphoblastic leukaemia25 recruiting
Kidney cancer25 recruiting
Melanoma24 recruiting
Triple-negative breast cancer19 recruiting
Liver and biliary tract cancer18 recruiting
Myelodysplastic syndromes18 recruiting
Myeloproliferative neoplasms16 recruiting
Diffuse large B-cell lymphoma11 recruiting
Glioblastoma10 recruiting
Chronic lymphocytic leukaemia9 recruiting
Hodgkin lymphoma8 recruiting
Mesothelioma8 recruiting
Neuroblastoma7 recruiting
Thyroid cancer7 recruiting
Cervical cancer6 recruiting
Chronic myeloid leukaemia6 recruiting
Follicular lymphoma6 recruiting
Brain metastases5 recruiting
Neuroendocrine tumours5 recruiting
Aplastic anaemia4 recruiting
Mantle cell lymphoma4 recruiting
Amyloidosis3 recruiting
Deep vein thrombosis and pulmonary embolism3 recruiting
HIV3 recruiting
Burkitt lymphoma2 recruiting
Down syndrome2 recruiting
Immune thrombocytopenia (ITP)2 recruiting
Meningioma2 recruiting
Neurofibromatosis type 12 recruiting
Testicular cancer2 recruiting
Chronic kidney disease1 recruiting
Cushing's syndrome1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Haemophagocytic lymphohistiocytosis1 recruiting
Insomnia1 recruiting
Myocarditis1 recruiting
Obesity1 recruiting
Osteoporosis1 recruiting
Pituitary tumours1 recruiting

Closed trials

Withdrawn
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
NCT07414992· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Withdrawn
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
NCT07353957· Phase 2· Genmab· Source
Withdrawn
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
NCT07428044· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Completed
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
NCT06863233· Phase 1· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908· Phase 1· EMD Serono Research & Development Institute, Inc.· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Terminated
A Study of PHN-010 in Patients With Advanced Solid Tumors
NCT06457997· Phase 1· Pheon Therapeutics· Source
Completed
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559· Phase 2· Eisai Inc.· Source
Terminated
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
NCT06566092· Phase 1· Iovance Biotherapeutics, Inc.· Source
Terminated
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
NCT06333678· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Completed
COVID19 OutcomeS in Myeloma and the Impact of VaCcines
NCT05831787· ASH Research Collaborative· Source
Completed
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793· Phase 3· Boehringer Ingelheim· Source
Terminated
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT06065059· Phase 1/2· Tango Therapeutics, Inc.· Source
Terminated
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
NCT05712694· Phase 3· Polaris Group· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Completed
A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer
NCT06145412· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Completed
A Study of Avutometinib for People With Solid Tumor Cancers
NCT06104488· Phase 1· Memorial Sloan Kettering Cancer Center· Source
Terminated
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
NCT05883449· Phase 2· Affimed GmbH· Source
Terminated
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
NCT05908396· Phase 1· IGM Biosciences, Inc.· Source
Withdrawn
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05918250· Phase 1· ModernaTX, Inc.· Source
Terminated
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
NCT05980416· Phase 1· Elevation Oncology· Source
Completed
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT05975073· Phase 1/2· Amgen· Source
Terminated
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NCT05935748· Phase 2· NiKang Therapeutics, Inc.· Source
Completed
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691· Phase 2· Hoffmann-La Roche· Source
Terminated
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
NCT05934630· Pediatric Brain Tumor Consortium· Source
Terminated
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05553639· Phase 1/2· Hookipa Biotech GmbH· Source
Completed
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
NCT05775406· Phase 1· Kymera Therapeutics, Inc.· Source
Completed
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
NCT05639751· Phase 1· Prelude Therapeutics Incorporated· Source
Terminated
A Study of XmAb23104 in People With Sarcoma
NCT05879185· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Terminated
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
NCT05731947· Phase 1/2· Syndax Pharmaceuticals· Source
Completed
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
NCT05759949· Phase 1· Relay Therapeutics, Inc.· Source
Completed
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183· Phase 2· Agenus Inc.· Source
Terminated
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT05827614· Phase 1· Boundless Bio, Inc.· Source
Terminated
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
NCT05788289· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Terminated
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05514717· Phase 1· Day One Biopharmaceuticals, Inc.· Source
Completed
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
NCT05619744· Phase 1· Hoffmann-La Roche· Source
Terminated
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05556616· Phase 1· Teva Branded Pharmaceutical Products R&D LLC· Source
Completed
A Multicenter Study to Evaluate the Cios Spin and the Ion Endoluminal System for Pulmonary Nodule Biopsy
NCT05562895· Intuitive Surgical· Source
Completed
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05271604· Phase 2· BioAtla, Inc.· Source
Completed
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377· Phase 2· Boehringer Ingelheim· Source
Terminated
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
NCT05682170· Phase 1/2· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Source
Terminated
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
NCT05617755· Phase 1· Arsenal Biosciences, Inc.· Source
Terminated
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
NCT05588609· Phase 2· Partner Therapeutics, Inc.· Source
Terminated
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
NCT05130255· Phase 1· Y-mAbs Therapeutics· Source
Completed
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
NCT05524545· Phase 1· ALX Oncology Inc.· Source
Completed
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
NCT04593277· Fred Hutchinson Cancer Center· Source
Terminated
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
NCT05569512· Phase 1· Malika Kapadia· Source
Terminated
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source
Completed
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
NCT05307328· Phase 2· Sparrow Pharmaceuticals· Source
Withdrawn
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
NCT04315246· Phase 1/2· Y-mAbs Therapeutics· Source

Showing 50 of 443.

Registry name variants (94)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Memorial Sloan-Kettering Cancer Center
New York, New York 10065
1,294 trials
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York 10065
182 trials
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York 10065
34 trials
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York 10065
27 trials
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey 07920
17 trials
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York 10021
15 trials
Memorial Sloan Kettering Cancer Ctr
New York, New York 10065
15 trials
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
Long Island City, New York 11101
10 trials
Memorial Sloan Kettering Cancer Center
Long Island City, New York 11101
7 trials
Memorial Sloan-Kettering Cancer Center (Mskcc) - New York
New York, New York 10065
7 trials
Memorial Sloan Kettering Cancer Center - New York
New York, New York 10065
7 trials
Memorial Sloan Kettering Cancer Center
Commack, New York 11725
5 trials
Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center
New York, New York 10065
5 trials
Memorial Sloan Kettering Cancer Center
Middletown, New Jersey 07748
4 trials
Memorial Sloan Kettering Cancer Center
Harrison, New York 10604
3 trials
- NCT04521686Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
- NCT03504397A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
- NCT03009981A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Memorial Sloan Kettering Cancer Center (IDS Pharmacy)
Long Island City, New York 11101
3 trials
- NCT07028853This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- NCT05059522Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- NCT04553133PF-07104091 as a Single Agent and in Combination Therapy
Memorial Sloan Kettering Cancer Center - MAIN
New York, New York 10065
3 trials
- NCT06731478Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
- NCT02629692Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Memorial Sloan Kettering Cancer Center (Adults and Pediatrics)
New York, New York 10065
2 trials
- NCT04554914A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
- NCT03394365A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  Contact: Data Protection Officer
Memorial Sloan Kettering Cancer Center (All Study Activities)
New York, New York 10065
2 trials
- NCT04734145Using e-Nose Technology to Identify Early Lung Cancer
- NCT04569773Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Memorial Sloan Kettering Cancer Center - New York - York Avenue- Site Number : 8400003
New York, New York 10065
2 trials
- NCT06356571A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT03284957Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center - NYC
New York, New York 10065
2 trials
- NCT06402331FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  Contact: Novartis Pharmaceuticals
Memorial Sloan Kettering Cancer Center (Site 0060)
New York, New York 10065
2 trials
- NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
- NCT03407144Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Memorial Sloan Kettering Cancer Center (Site 0142)
New York, New York 10022
2 trials
- NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
  Contact: Principal Investigator
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Memorial Sloan Kettering Cancer Center (Site 1002)
New York, New York 10065
2 trials
- NCT05007106MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- NCT04626479Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Memorial Sloan Kettering Cancer Centre
New York, New York 10065
2 trials
- NCT05755113A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
  Contact: Edmund Bartlett (principal investigator)
- NCT02582697Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
  Contact: Victoria Martorana
David H Koch, Memorial Sloan Kettering Cancer Center
New York, New York 10021
1 trial
- NCT05245500Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
  Contact: Kathryn Arbour, Site 104
Evelyn H. Lauder Breast Center - Memorial Sloan Kettering Cancer Center
New York, New York 10065
1 trial
- NCT04229004A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Manhattan, New York 10065
1 trial
- NCT05731947Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Montvale, New Jersey 07645
1 trial
- NCT03504397A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Memorial Sloan Kettering Cancer Center
Uniondale, New York 11553
1 trial
- NCT03504397A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Memorial Sloan-Kettering Cancer Center
Tampa, Florida 33612
1 trial
- NCT03504488CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Memorial Sloan Kettering Cancer Center - 1275 York Ave
New York, New York 10065-6635
1 trial
- NCT07015190Neoadjuvant Darovasertib in Primary Uveal Melanoma
  Contact: Jasmine Francis, MD Principal Investigator
Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
New York, New York 10021
1 trial
- NCT06154252RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
  Contact: Atifah Osrat
Memorial Sloan Kettering Cancer Center - Adults
New York, New York 10065
1 trial
- NCT06001385HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Memorial Sloan Kettering Cancer Center - Bergen
New York, New York 10065
1 trial
- NCT07121946This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
  Contact: Pallawi Torka, MD
Memorial Sloan Kettering Cancer Center - Commack
New York, New York 10087-9049
1 trial
- NCT03274492A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center (Consent and Follow-Up)
New York, New York 10065
1 trial
- NCT02414269Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan-Kettering Cancer Center - Hematology Service MSKCC
New York, New York 10065
1 trial
- NCT07723703Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
  Contact: Amphista Medical Monitor
Memorial Sloan Kettering Cancer Center /ID# 243503
New York, New York 10065-6007
1 trial
- NCT05308654A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Memorial Sloan Kettering Cancer Center /ID# 244656
New York, New York 10065-6007
1 trial
- NCT05259839A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center /ID# 271228
New York, New York 10021-3459
1 trial
- NCT06858813A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Memorial Sloan Kettering Cancer Center - KOCH
New York, New York 10021
1 trial
- NCT05210790A Study of Rusfertide in Adults With Polycythemia Vera (PV)
Memorial Sloan Kettering Cancer Center - Main
Long Island City, New York 11101
1 trial
- NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Memorial Sloan Kettering Cancer Center - Melanoma & Immunotherapeutics
New York, New York 10065
1 trial
- NCT05533697Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
  Contact: Moderna WeCare Team
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc
New York, New York 10022
1 trial
- NCT06641908Anti-GD2 ADC M3554 in Advanced Solid Tumors
  Contact: Communication Center
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132
New York, New York 10065
1 trial
- NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282
New York, New York 10065
1 trial
- NCT06896916Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214
New York, New York 10065
1 trial
- NCT06953960A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999
New York, New York 10065
1 trial
- NCT07196644A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946
New York, New York 10065
1 trial
- NCT07095452A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Memorial Sloan Kettering Cancer Center - New York - York Avenue- Site Number : 8400001
New York, New York 10065
1 trial
- NCT07116031A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Memorial Sloan Kettering Cancer Center (only recruiting to the Vascular/Angiosarcoma cohort)
New York, New York 10065
1 trial
- NCT03282344A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center (Outpatient Center)
New York, New York 10065
1 trial
- NCT03530683A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Memorial Sloan Kettering Cancer Centers
New York, New York 10022
1 trial
- NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
  Contact: Clinical Trial Disclosure & Transparency
Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers
New York, New York 10065
1 trial
- NCT06995677Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
  Contact: Gina Risdall
Memorial Sloan Kettering Cancer Center (Site 0003)
New York, New York 10065
1 trial
- NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 0006)
New York, New York 10065
1 trial
- NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 0009)
New York, New York 10065
1 trial
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Memorial Sloan Kettering Cancer Center (Site 0014)
New York, New York 10065
1 trial
- NCT03833180A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Memorial Sloan Kettering Cancer Center (Site 0015)
New York, New York 10065
1 trial
- NCT04704219Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Memorial Sloan-Kettering Cancer Center (Site 0017)
New York, New York 10065
1 trial
- NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Memorial Sloan Kettering Cancer Center (Site 0029)
New York, New York 10065
1 trial
- NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Memorial Sloan Kettering Cancer Center (Site 0032)
New York, New York 10065
1 trial
- NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Memorial Sloan Kettering Cancer Center (Site 0055)
New York, New York 10065
1 trial
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Memorial Sloan Kettering Cancer Center (Site 0067)
New York, New York 10065
1 trial
- NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 0069)
New York, New York 10021
1 trial
- NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Memorial Sloan Kettering Cancer Center (Site 0072)
New York, New York 10022
1 trial
- NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 0095)
New York, New York 10065
1 trial
- NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 0100)
New York, New York 10065
1 trial
- NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Memorial Sloan Kettering Cancer Center (Site 0102)
New York, New York 10065
1 trial
- NCT05446870Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Memorial Sloan Kettering Cancer Center (Site 0113)
New York, New York 10065
1 trial
- NCT03516981A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Memorial Sloan Kettering Cancer Center (Site 0115)
New York, New York 10065
1 trial
- NCT04924101Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
Memorial Sloan Kettering Cancer Center (Site 0126)
New York, New York 10065
1 trial
- NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 0132)
New York, New York 10065
1 trial
- NCT04949256Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Memorial Sloan Kettering Cancer Center (Site 0137)
New York, New York 10065
1 trial
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 0246)
New York, New York 10022
1 trial
- NCT03884101Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
Memorial Sloan Kettering Cancer Center (Site 0832)
New York, New York 10065
1 trial
- NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 1010)
New York, New York 10065
1 trial
- NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 1031)
New York, New York 10065
1 trial
- NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Memorial Sloan Kettering Cancer Center (Site 108)
New York, New York 10065
1 trial
- NCT07265674A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
  Contact: Masuhiro Yoshitake
Memorial Sloan-Kettering Cancer Center (Site 1661)
New York, New York 10065
1 trial
- NCT03976375Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Memorial Sloan Kettering Cancer Center (Site 1703)
New York, New York 10065
1 trial
- NCT05064059A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Memorial Sloan Kettering Cancer Center (Site 1857)
New York, New York 10021
1 trial
- NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
Memorial Sloan Kettering Cancer Center (Site 1914)
New York, New York 10065
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Memorial Sloan Kettering Cancer Center (Site 210)
New York, New York 10065
1 trial
- NCT04283669Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Memorial Sloan Kettering Cancer Center (Site 3002)
New York, New York 10065
1 trial
- NCT04626518Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Memorial Sloan Kettering Cancer Center (Site 3010)
New York, New York 10065
1 trial
- NCT06941272A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 3031)
New York, New York 10065
1 trial
- NCT05845814A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Memorial Sloan Kettering Cancer Center (Site 3568)
New York, New York 10065
1 trial
- NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Memorial Sloan Kettering Cancer Center (Site 4010)
New York, New York 10065
1 trial
- NCT07630974A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 5002)
New York, New York 10065
1 trial
- NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 5031)
New York, New York 10065
1 trial
- NCT07232602KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (Site 6053)
New York, New York 10065
1 trial
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York 10021

Conditions

Diseases this institution publishes on or runs trials for.

Lung cancer401 works · 250 trials
Prostate cancer260 works · 143 trials
Melanoma216 works · 87 trials
Multiple myeloma169 works · 118 trials
Colorectal cancer153 works · 120 trials
Liver and biliary tract cancer138 works · 62 trials
Sarcoma138 works · 132 trials
Ovarian cancer130 works · 122 trials
Kidney cancer125 works · 79 trials
Pancreatic cancer122 works · 99 trials
Acute myeloid leukaemia104 works · 87 trials
Bladder cancer94 works · 88 trials
Hodgkin lymphoma92 works · 33 trials
Brain metastases89 works · 17 trials
Triple-negative breast cancer74 works · 47 trials
Endometrial cancer70 works · 74 trials
Metastatic breast cancer63 works · 75 trials
Gastric and oesophageal cancer54 works · 74 trials
Glioblastoma53 works · 43 trials
Head and neck cancer52 works · 75 trials
Acute lymphoblastic leukaemia52 works · 68 trials
Neuroendocrine tumours45 works · 21 trials
Cervical cancer42 works · 24 trials
Diffuse large B-cell lymphoma41 works · 37 trials
Myelodysplastic syndromes39 works · 43 trials
Myeloproliferative neoplasms37 works · 35 trials
Follicular lymphoma36 works · 23 trials
Childhood cancers35 works · 298 trials
Thyroid cancer35 works · 37 trials
Deep vein thrombosis and pulmonary embolism31 works · 5 trials

Institution data: ROR 02yrq0923 (CC0-1.0)Updated 14 Nov 2026

Report an error